Literature DB >> 35440813

Ventricular enlargement caused by aducanumab.

Scott Ayton1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35440813     DOI: 10.1038/s41582-022-00660-7

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   44.711


× No keyword cloud information.
  1 in total

1.  Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.

Authors:  S Budd Haeberlein; P S Aisen; F Barkhof; S Chalkias; T Chen; S Cohen; G Dent; O Hansson; K Harrison; C von Hehn; T Iwatsubo; C Mallinckrodt; C J Mummery; K K Muralidharan; I Nestorov; L Nisenbaum; R Rajagovindan; L Skordos; Y Tian; C H van Dyck; B Vellas; S Wu; Y Zhu; A Sandrock
Journal:  J Prev Alzheimers Dis       Date:  2022
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.